Delivery Order SPE2DB22D2206-SPE2DB26FDU91
- Not listed
- The Defense Logistics Agency awarded a $2,168.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Testopel 75 mg pellets (10-count units) on October 20, 2025, with an ultimate completion date of November 10, 2025. This non-competitive, non-set-aside delivery order represents a pharmaceutical supply transaction supporting federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $7,968.84 to AmerisourceBergen Drug Corp for Testopel 75 mg pellets (100-count units) on October 22, 2025, with an ultimate completion date of November 13, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for Testopel 75 mg pellets valued at $10,289.00. This delivery order, issued on August 25, 2025, represents a firm fixed price contract with performance expected to conclude by September 16, 2025. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established capability to...
- The Defense Logistics Agency awarded a $2,057.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Testopel 75 mg pellets (10 count) on October 16, 2025, with completion targeted for November 6, 2025. This non-set-aside award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $4,115.60 to AmerisourceBergen Drug Corp for the supply of Testopel 75 mg pellets (10-count units). This firm fixed-price delivery order, issued on April 23, 2025, with an ultimate completion date of May 14, 2025, represents a non-competitive procurement under an existing contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $8,231.20 to AmerisourceBergen Drug Corp for the supply of Testopel 75 mg pellets (10 units) on September 17, 2025. This competitive, firm fixed-price delivery order is scheduled for completion by October 8, 2025, with fulfillment based at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Testopel 75 mg pellets (100-count units) with a ceiling value of $8.2K. This is a firm fixed price delivery order with no set-aside designation, issued under competitive procedures and scheduled for completion by September 5, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a $4,115.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Testopel 75 mg pellets (100-count units) on May 2, 2025, with an ultimate completion date of May 23, 2025. This non-competitive delivery order will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child contract under a larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,057.80 to AmerisourceBergen Drug Corp for Testopel 75 mg pellets on June 11, 2025, with a completion date of July 3, 2025. This firm fixed price delivery order represents a non-competitive set-aside transaction and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Testopel is a testosterone replacement therapy product used in hormone treatment applications within military and federal healthcare...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,346.74 to AmerisourceBergen Drug Corp for the supply of Testopel 75 mg pellets (100-count units) with a completion date of September 11, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and is classified as a delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB26FDU91Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,231.14 to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Testopel 75 mg pellets (100 count). This is a firm fixed-price delivery order with no set-aside designation, reflecting open competition for the award. The contract will be performed at the company's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of November 20, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor, is fulfilling this order as a child contract under its larger prime indefinite delivery contract (IDC) with DLA Troop Support Medical. This delivery order represents a routine pharmaceutical supply transaction supporting military and federal healthcare systems. AmerisourceBergen Drug Corp holds a significant $999.999 billion IDC with DLA Troop Support Medical (SPE2DX) through December 2026, which serves as the overarching vehicle for pharmaceutical procurement across multiple therapeutic domains for Department of Defense and other federal health programs. The company's extensive federal contract portfolio demonstrates its established capability to supply specialized medications, including hormone treatments and other pharmaceutical products, to support military healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.2k | 10/29/25 |